Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 29:13:90.
doi: 10.1186/1476-511X-13-90.

In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients

Vasiliki D Papakonstantinou  1 , Maria Chini, Nikos Mangafas, George M Stamatakis, Nickolaos Tsogas, Alexandros B Tsoupras, Katherina Psarra, Elizabeth Fragopoulou, Smaragdi Antonopoulou, Panagiotis Gargalianos, Constantinos A Demopoulos, Marios-C Lazanas
Affiliations

In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients

Vasiliki D Papakonstantinou et al. Lipids Health Dis. .

Abstract

Background: Persistent immune activation and inflammation are lying behind HIV-infection even in the setting of ART mediated viral suppression. The purpose of this study is to define the in vivo effect of two first-line ART regimens on certain inflammatory mediators in male HIV patients.

Methods: Male, naive, HIV-infected volunteers were assigned either to tenofovir-DF/emtricitabine/efavirenz (Group_T) or abacavir/lamivudine/efavirenz (Group_A). Platelet Activating Factor (PAF) levels and metabolic enzymes together with HIV-implicated cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, TNFa) and VEGF were determined for a 12-month period. Differences within each group were determined by non-parametric Friedman and Wilcoxon test, while the differences between the groups were checked by ANOVA repeated measures.

Results: Both ART regimens present pronounced effect on inflammatory mediators, resulting in decreased PAF levels and Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity for tenofovir-containing regimen and same as baseline PAF levels with a peak though at the 3rd month as well as elevated Lp-PLA2 activity for abacavir-containing regimen.

Conclusions: Studies regarding the effect of first-line ART regimens on inflammation may be beneficial in preventing chronic morbidities during HIV-treatment. From this point of view, the present study suggests an anti-inflammatory effect of tenofovir-containing ART, while the temporary increase of PAF levels in abacavir-containing ART may be the link between the reported cardiovascular risk and abacavir administration.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of Bound PAF levels between the ART groups, Group_T: tenofovir-DF/emtricitabine/efavirenz, Group_A: abacavir/lamivudine/efavirenz, Data are expressed as median values and interquartile range (25th-75th). Pint. displays the overall difference between the two groups. P displays the difference at a particular time point of the study occurred from the comparison of the two groups.
Figure 2
Figure 2
Comparison of Lp-PLA2 specific activity between the ART groups, Group_T: tenofovir-DF/emtricitabine/efavirenz, Group_A: abacavir/lamivudine/efavirenz, Data are expressed as median values and interquartile range (25th-75th). Pint. displays the overall difference between the two groups. P displays the difference at a particular time point of the study occurred from the comparison of the two groups.
See this image and copyright information in PMC

References

    1. Taiwo B, Barcena L, Tressler R. Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy. Curr HIV/AIDS Rep. 2013;10:21–32. doi: 10.1007/s11904-012-0147-3. - DOI - PubMed
    1. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep. 2012;9:139–147. doi: 10.1007/s11904-012-0118-8. - DOI - PubMed
    1. Plaeger SF, Collins BS, Musib R, Deeks SG, Read S, Embry A. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses. 2012;28:469–477. - PMC - PubMed
    1. Miller CJ, Baker JV, Bormann AM, Erlandson KM, Huppler Hullsiek K, Justice AC, Neuhaus J, Paredes R, Petoumenos K, Wentworth D, Winston A, Wolfson J, Neaton JD, Insight S, Groups ES. Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy. PloS one. 2014;9:e95061. doi: 10.1371/journal.pone.0095061. - DOI - PMC - PubMed
    1. Venketaraman V, Morris D, Donohou C, Sipin A, Kung S, Oh H, Franklin M, Murad JP, Khasawneh FT, Saviola B, Guilford T, Donahue C. In: HIV and AIDS - Updates on Biology, Immunology, Epidemiology and Treatment Strategies. Dumais N, editor. Croatia: InTech; 2011. Role of Cytokines and Chemokines in HIV Infection; pp. 281–300.

Publication types

MeSH terms